JNJ

233.9

+0.21%↑

UNH

278.18

-1.9%↓

TMO

572.77

-1.84%↓

ABT

108.41

+0.25%↑

ISRG

475.79

-3%↓

JNJ

233.9

+0.21%↑

UNH

278.18

-1.9%↓

TMO

572.77

-1.84%↓

ABT

108.41

+0.25%↑

ISRG

475.79

-3%↓

JNJ

233.9

+0.21%↑

UNH

278.18

-1.9%↓

TMO

572.77

-1.84%↓

ABT

108.41

+0.25%↑

ISRG

475.79

-3%↓

JNJ

233.9

+0.21%↑

UNH

278.18

-1.9%↓

TMO

572.77

-1.84%↓

ABT

108.41

+0.25%↑

ISRG

475.79

-3%↓

JNJ

233.9

+0.21%↑

UNH

278.18

-1.9%↓

TMO

572.77

-1.84%↓

ABT

108.41

+0.25%↑

ISRG

475.79

-3%↓

Strona główna・Stock List・Denali Therapeutics Inc

Denali Therapeutics Inc

Open

SectorHealthcare

20.78 -7.85

Buy Sell

Overview

Share price change

24h

Current

Min

20.62

Max

22.27

Key metrics
By Trading Economics
Income	-2.8M -127M
Employees	517
EBITDA	-12M -134M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+45.12% upside

Dividends
By Dow Jones
Next Earnings	25 lut 2026

Market Stats
By TradingEconomics
Market Cap	973M 3.2B
Previous open	28.63
Previous close	20.78

News Sentiment

By Acuity

63%

37%

305 / 352 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

13.355 / 16.44 Support & Resistance

Denali Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 lut 2026, 23:11 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3 lut 2026, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 lut 2026, 23:50 UTC

Market Talk

Nikkei May Decline After Hitting All-Time High -- Market Talk

3 lut 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

3 lut 2026, 23:41 UTC

Acquisitions, Mergers, Takeovers

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3 lut 2026, 23:38 UTC

Earnings

AMD Sales Climb on Help From Data-Center Business -- Update

3 lut 2026, 23:29 UTC

Acquisitions, Mergers, Takeovers

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3 lut 2026, 23:27 UTC

Acquisitions, Mergers, Takeovers

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3 lut 2026, 23:25 UTC

Acquisitions, Mergers, Takeovers

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3 lut 2026, 23:23 UTC

Acquisitions, Mergers, Takeovers

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3 lut 2026, 23:22 UTC

Acquisitions, Mergers, Takeovers

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3 lut 2026, 23:19 UTC

Market Talk

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3 lut 2026, 23:19 UTC

Market Talk

Global Equities Roundup: Market Talk

3 lut 2026, 22:56 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3 lut 2026, 22:40 UTC

Earnings

Amdocs Extends Collaboration With T-Mobile

3 lut 2026, 22:39 UTC

Earnings

Amdocs 1Q Adj EPS $1.81

3 lut 2026, 22:39 UTC

Earnings

Amdocs 1Q Rev $1.16B

3 lut 2026, 22:39 UTC

Earnings

Amdocs 1Q EPS $1.45 >

3 lut 2026, 22:38 UTC

Earnings

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3 lut 2026, 22:30 UTC

Acquisitions, Mergers, Takeovers

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3 lut 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3 lut 2026, 22:14 UTC

Earnings

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3 lut 2026, 22:13 UTC

Earnings

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3 lut 2026, 22:12 UTC

Earnings

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3 lut 2026, 22:10 UTC

Earnings

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3 lut 2026, 22:10 UTC

Earnings

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3 lut 2026, 22:10 UTC

Market Talk

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3 lut 2026, 22:10 UTC

Earnings

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3 lut 2026, 22:09 UTC

Earnings

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3 lut 2026, 22:09 UTC

Earnings

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Peer Comparison

Price change

Denali Therapeutics Inc Forecast

Price Target

By TipRanks

45.12% upside

12 Months Forecast

Average 33 USD 45.12%

High 40 USD

Low 25 USD

Based on 12 Wall Street analysts offering 12 month price targets forDenali Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Denali Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

13.355 / 16.44Support & Resistance

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentiment

By Acuity

305 / 352 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.